The active ingredient clomazone is of moderate acute toxicity after oral and inhalation exposure
and of low dermal toxicity. The product Centium is of low acute toxicity after oral exposure, by
skin contact or by inhalation; however the product may contain a co-formulant, monomeric
isocyanate, with sensitizing properties. Due to the lack of documentation on the monomer
content, the Panel can not evaluate the risk of sensitization. UK Poem model estimation of
exposure show that exposure to operator is below AOEL and the health risk is therefore minimal.